# Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

> **NCT01294436** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 728 (actual)

## Conditions studied

- Type2 Diabetes
- High Blood Sugar

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT01294436
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 728 (ACTUAL)
- **Last updated:** 2013-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294436, "Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01294436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*